位置:首页 > 医药大数据 > 免疫治疗 > > PD-1/PD-L1
PD-1/PD-L1

印度PD-1/PD-L1

资料发布时间:2018-10-30 14:50:00 最后更新时间: 2021-06-09 15:17:08

【药品简介】 适应症: 白血病、淋巴瘤 :慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤(CLL/SLL),以及带有17p缺失突变的CLL/SLL;用于治疗既往接受过治疗的套细胞淋巴瘤(MCL);用于治疗Waldenstrm macroglobulinemia 作用机制: 依鲁替尼(Ibrutinib)是小分子BTK 抑制药

【适应症状】 PD-1/PD-L1,适应症: 白血病、淋巴瘤 :慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤(CLL/SLL),以及带有17p缺失突变的CLL/SLL;用于治疗既往接受过治疗的套细胞淋巴瘤(MCL);用于治疗Waldenstrm macroglobulinemia 作用机制: 依鲁替尼(Ibrutinib)是小分子BTK 抑制药

【 药品别名 】 依鲁替尼 Ibrutinib Emlutini

印度PD-1/PD-L1(依鲁替尼 Ibrutinib Emlutini)价格,正品图片,治疗免疫治疗药物, 购买PD-1/PD-L1请到印度药房官方网站进行购买 【印度药房大全目录】

【 市场参考价格 】 ¥2120.00~2360.00

播放/暂停

印度全球药房排名

【印度PD-1/PD-L1说明书,怎么吃?】

PD-1/PD-L1(印度)又名依鲁替尼 Ibrutinib Emlutini,PD-1/PD-L1适用于适应症: 白血病、淋巴瘤 :慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤(CLL/SLL),以及带有17p缺失突变的CLL/SLL;用于治疗既往接受过治疗的套细胞淋巴瘤(MCL);用于治疗Waldenstrm macroglobulinemia 作用机制: 依鲁替尼(Ibrutinib)是小分子BTK 抑制药的治疗,PD-1/PD-L1用法及注意事项,:作用机制: 依鲁替尼(Ibrutinib)是小分子BTK 抑制药,与BTK活性位点中的半胱氨酸残基形成共价键,从而抑制BTK酶的活性。研究显示,依鲁替尼具有抑制恶性B细胞增殖和体内的存活以及体外细胞迁...

PD-1依鲁替尼作用机制:

依鲁替尼(Ibrutinib)是小分子BTK 抑制药,与BTK活性位点中的半胱氨酸残基形成共价键,从而抑制BTK酶的活性。研究显示,依鲁替尼具有抑制恶性B细胞增殖和体内的存活以及体外细胞迁移和底物的黏附作用。
 
参考用法:

1. CLL/SLL:口服,420mg 每天一次(单药或与苯达莫司汀/美罗华联用);直至疾病进展或不可接受的毒性。
 
2. CLL/SLL(含17p缺失):口服,420mg 每天一次;直至疾病进展或不可接受的毒性
 
3. 套细胞淋巴瘤,经治:口服,560mg 每天一次,直至疾病进展或不可接受的毒性
 
4. Waldenström macroglobulinemia:口服,420mg 每天一次,直至疾病进展或不可接受的毒性
 
 
 
PD-1依鲁替尼常见副作用:

头痛、劳累、早饱、恶心呕吐、腹痛、腹泻、便秘、肌肉痛、关节痛等

临床试验中,在接受过治疗的CLL患者中,总反应率为58.3%,缓解持续时间为5.6-24.2月;套细胞淋巴瘤,总反应率位65.8%,缓解持续时间为17.5月。

PD-1依鲁替尼英文原版说明书

Ibrutinib uses

Ibrutinib is used in the treatment of mantle-cell lymphoma and blood cancer (chronic lymphocytic leukemia). It is also used in chronic lymphocytic leukaemia who have received at least one prior therapy or with 17p deletion.

How ibrutinib works

Ibrutinib is a Bruton's tyrosine kinase inhibitor. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Common side effects of ibrutinib

Headache, Joint pain, Fever, Diarrhea, Vomiting, Stomatitis (Inflammation of the mouth), Nausea, Constipation, Low blood platelets, Decreased white blood cell count (neutrophils), Upper respiratory tract infection

Ibrutinib

生物活性

产品描述

Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.

靶点活性

BLK,0.5 nM (cell free)

Bmx,0.8 nM (cell free)

BTK,0.5 nM (cell free)

CSK,2.3 nM (cell free)

FGR,2.3 nM (cell free)

BRK,3.3 nM (cell free)

实验溶液

2% DMSO+castor oil: 10 mg/mL

体外活性

In DOHH2, a cell line in which the BCR pathway can be activated by stimulation with anti-IgG, Ibrutinib (PCI-32765) inhibits autophosphorylation of Btk (IC50: 11 nM), phosphorylation of Btk's physiological substrate PLCγ (IC50: 29 nM), and phosphorylation of a further downstream kinase, ERK (IC50: 13 nM). Continuous exposure to 10 nM PCI-32765 for 18 h completely prevented up-regulation of the B-cell activation marker CD69. A 1-h pulse exposure to 10 nM PCI-32765 resulted in a similar level of CD69 inhibition in B cells [1]. PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50: 8 nM). Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 production in primary monocytes (IC50s: 2.6/0.5/3.9 nM). Following FcεRI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD(2), TNF-α, IL-8, and MCP-1 [2]. Treatment of CD40 or BCR activated CLL cells with PCI-32765 results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-κB. In addition, PCI-32765 inhibits activation-induced proliferation of CLL cells in vitro and effectively blocks survival signals provided externally to CLL cells from the microenvironment [3].

体内活性

PCI-32765 (3.125, 12.5, or 50 mg/kg per day) markedly inhibited clinical arthritis scores. Partial and nearly complete elimination of clinical signs of the disease occurred after 9 to 11 d of treatment at dosages of 3.125 and 12.5 mg/kg per day, respectively. An oral single dose of PCI-32765 at 3.125 mg/kg per day resulted in partial Btk occupancy in splenocytes, and the maximally efficacious dose (12.5 mg/kg per day) was sufficient to fully occupy Btk for 12 h [1]. PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model (ED50: 2.6 mg/kg/day). PCI-32765 also prevented clinical arthritis in CAIA models. In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited [2].

激酶实验

In vitro kinase IC50s were measured using 33P filtration binding assay after 1 h incubation of kinase, 33P-ATP, inhibitor, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays were performed at Reaction Biology [1].

细胞实验

CD20+ B and CD3+ T cells were purified by negative selection (RosetteSep, >90% purity) from buffy coat PBMCs and viably frozen in 10% DMSO. Cells were thawed at 37 °C and maintained in growth media (RPMI media containing 10% FCS). B cells were stimulated with goat anti-human IgM F(ab′)2 (10 μg/mL) and T cells were stimulated with anti-CD3/CD28 coated beads at a 1:1 bead/cell ratio. Cells were stained with PE-CD69 and analyzed by flow cytometry, gating on viable lymphocytes. PCI-32765 at concentrations lower than 10 μM did not decrease B- or T-cell viability during the course of the experiment, although PCI-32765 did block the modest survival benefit of anti-IgM stimulation in B cells. For washout experiments, cells were rinsed three times in 10 volumes of growth media, a protocol that was confirmed to completely wash away inhibition of BCR signaling by PCI-29732, a reversible Btk inhibitor [1].

细胞系: Chronic lymphocytic leukemia (CLL) cells

动物实验

ale DBA/1 mice were immunized with type II collagen plus Freund adjuvant and boosted 21 d later. On a rolling basis, as significant swelling appeared in at least one paw, mice were enrolled and randomized. PCI-32765 or dexamethasone (0.2 mg/kg) was administered orally once per day for 11 d. Arthritis scores (0–5) were assigned to the mice based on the degree and extent of paw swelling. Mouse anti-type II collagen antibody and total IgG levels were measured by ELISA. Female MRL/MpJ-Faslpr mice received PCI-32765 by oral gavage once per day from week 8 through week 20. Proteinuria was monitored weekly. At week 20, serum was collected and analyzed for BUN and mouse anti-dsDNA antibody levels. Kidney histology was scored according to established criteria (26). No drug-induced weight loss was observed at any of the dose levels tested. These studies were carried out at Boulder Biopath according to approved animal care protocols. Results are presented as the mean ± SEM. Statistical significance between groups were evaluated with repeated measures one-way ANOVA or one-way ANOVA using GraphPad Prism with Tukey or Bonferroni multicomparison posttest [1].

动物模型:MRL-Fas(lpr) lupus model and collagen-induced arthritis model.

化学信息

分子量

440.50

分子式

C25H24N6O2

CAS

936563-96-1

溶解度

DMSO: 82 mg/mL (186.2 mM)

Ethanol: <1 mg/mL

Water: <1 mg/mL

( < 1 mg/ml refers to the product slightly soluble or insoluble )

储存条件

store at -80°C

备注

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

配制溶液

  1 mg 5 mg 10 mg
1 mM 2.27 ml 11.351 ml 22.701 ml
5 mM 0.454 ml 2.27 ml 4.54 ml
10 mM 0.227 ml 1.135 ml 2.27 ml
50 mM 0.045 ml 0.227 ml 0.454 ml
参考文献
 
1. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
2. Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115.
3. Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9;117(23):6287-96.
注:本站PD-1/PD-L1(依鲁替尼 Ibrutinib Emlutini)药品说明,价格,正品图片均来自于官方,PD-1/PD-L1如何服用请尊医嘱。如需药品请到正规印度药房进行购买
上一篇:没有了 下一篇:没有了
PD-1/PD-L1相关药品
PD-1/PD-L1
PD-1/PD-L1

作用机制: 依鲁替尼(Ibrutinib)是小分子BTK 抑制药,与BTK活性位点中的半胱氨酸残基形成共价键,从而抑制B......

依鲁替尼
依鲁替尼

作用机制: 依鲁替尼(Ibrutinib)是小分子BTK 抑制药,与BTK活性位点中的半胱氨酸残基形成共价键,从而抑制B......

艾曲博帕
艾曲博帕

【药品特色】 艾曲波帕是一种促血小板生成素受体激动剂适用于治疗慢性免疫性血小板减少性紫癜患者的血小板减少,对皮质激素、免......

硼替佐米
硼替佐米

【药品特色】 硼替佐米是哺乳动物细胞中26S蛋白酶体糜蛋白酶样活性的可逆抑制剂。体外试验证明硼替佐米对多种类型的癌细胞具......

马法兰
马法兰

【禁忌症】 ALKERAN不应该用于那些疾病已经表现出对该药物有先前抗性的患者。 已证实对美法仑过敏的患者不应给予该药。......

伊马替尼
伊马替尼

【作用机制】 磺酸伊马替尼在体内外均可在细胞水平上抑制Bcr-Abl酪氨酸激酶,能选择性抑制Bcr-Abl阳性细胞系细胞......

PD-1/PD-L1资讯
伊马替尼治白血病
伊马替尼治白血病

第一代酪氨酸激酶抑制剂伊马替尼对CML的治疗具有重要价值,而干扰素α是TKI药物诞生前CML治疗的一线药物...

伊马替尼治白血病?
伊马替尼治白血病?

伊马替尼是一种常用于治疗白血病的药物。因为很多人对它并不真正了解或害怕它的“副作用”,所以对它有一些怀疑和误解。...

格列卫的副作用
格列卫的副作用

白血病是一种血液病,也称为血癌,治疗非常困难。骨髓移植是一种方法,但患者往往选择其他治疗方法,因为他们找不到合适的骨髓。......

急性白血病能用伊马替尼?
急性白血病能用伊马替尼?

通过说明,发现其治疗的白血病类型为慢性粒细胞白血病,可分为慢性期、加速期和急性期。伊马替尼是否也可用于急性白血病?...

伊马替尼治疗白血病
伊马替尼治疗白血病

慢性粒细胞白血病(CML)是由骨髓造血干细胞(BMSCs)克隆增殖而形成的血液系统恶性肿瘤。...

PD-1/PD-L1视频
什么是白血病?
什么是白血病?

白血病是一类造血干细胞恶性克隆性疾病...

中医与免疫治疗有什么关系?
中医与免疫治疗有什么关系?

中医有一句话叫做正气存内邪不可干,正气就包括了阴阳的平衡,气血、脏腑功能的平衡...

宝宝得了白血病还有救吗?
宝宝得了白血病还有救吗?

宝宝得了白血病不光有救,也有可能完全治愈,...

儿童白血病如何治疗?
儿童白血病如何治疗?

儿童白血病的治疗原则为早期诊断、早期治疗,有间歇、交替用药的方式,并坚持长期的治疗,预防复发。...

药房目录大全

Pharmacy Catalogue


联系人:
微信:
需要药品:
欢迎更多正规药房加入,如病友有发现销售伪冒药品的网站,也请告知本站,我们将推出黑名单曝光之。联系微信: sun24moon